ritetronium

RN given refers to parent cpd; structure

Also Known As:

Acolbifene; EM 652; EM-652; IEM 652; SCH 57068; SCH57068; bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate; bis(p-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate; ritebronii; ritebronium; ritetronium dibenzenesulfonate; ritetroniy; 1,1'-((1,3,6,8-tetrahydro-1,3,6,8-tetraoxobenzo(lmn)(3,8)phenanthroline-2,7-diyl)di-4,1-phenylene)bis(1-ethylpiperidinium),

Networked: 23 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - ritetronium: 23

Experts

1.	Labrie, Fernand: 9 articles (10/2006 - 05/2002)
2.	Labrie, F: 4 articles (10/2005 - 07/2001)
3.	Deshaies, Yves: 3 articles (05/2006 - 03/2003)
4.	Lemieux, Christian: 3 articles (05/2006 - 03/2003)
5.	Richard, Denis: 3 articles (05/2006 - 03/2003)
6.	Gélinas, Yves: 2 articles (05/2006 - 09/2005)
7.	Lalonde, Josée: 2 articles (05/2006 - 09/2005)
8.	Giguère, V: 2 articles (10/2005 - 12/2001)
9.	Candas, Bernard: 2 articles (03/2004 - 05/2002)
10.	Labrie, Claude: 2 articles (03/2004 - 05/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 12/01/2015 - "Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer." 02/01/2005 - "Acolbifene could also induce DNA damage in the S30 breast cancer cell line. " 02/01/2005 - "As a pure antagonist of breast tumor development and growth, acolbifene does not stimulate endometrial tissue. " 09/01/2004 - "Potentially, E(2) + SCH 57068 could be combined for the treatment and prevention of breast cancer or as a novel hormone replacement therapy." 12/01/2015 - "In summary, acolbifene was associated with favorable changes in benign breast epithelial cell proliferation and estrogen-inducible gene expression but minimal side effects, suggesting a phase IIB placebo-controlled trial evaluating it further for breast cancer prevention."
2.	Obesity 03/01/2003 - "EM-652 is an effective agent to prevent diet- and OVX-induced obesity and its associated cardiovascular risk factors such as insulin resistance. " 03/01/2003 - "This study aimed to assess the ability of EM-652, alone or with dehydroepiandrosterone (DHEA), to prevent obesity and related metabolic abnormalities induced by an obesity-promoting diet and ovariectomy. " 03/01/2003 - "The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity."
3.	Neoplasms (Cancer) 04/01/1999 - "EM-652 was also the most potent inhibitor of the percentage of cycling cancer cells. " 10/01/2003 - "Most importantly, 93% of the tumors which had become undetectable under EM-652 treatment did not reappear when exposed to estrogen challenge for 12 weeks, thus achieving an overall 61% cure rate. " 10/01/2003 - "EM-652 not only prevented estrogen-induced tumor growth but it reduced tumor size to 20% of the pretreatment value. " 05/01/2006 - "Acolbifene (ACOL) is a fourth-generation selective estrogen receptor modulator (SERM) that has strong and pure antiestrogenic properties toward estrogen-sensitive cancers, but improves energy and lipid metabolism in an estrogen-like fashion in rodent models. " 09/01/2005 - "The cancer-preventing selective estrogen receptor modulator (SERM) acolbifene (ACOL) exerts a potent and pure antiestrogenic action in the mammary gland and uterus, yet it displays beneficial, estrogen-like actions on energy and lipid metabolism in rodents. "
4.	Uterine Neoplasms (Uterine Cancer) 03/01/2003 - "EM-652 is a pure antiestrogen in human breast and uterine cancer cells that also reduces bone loss and plasma lipid levels in the rat. " 05/10/2002 - "Since previous data have shown benefits of EM-652 on bone density and lipid profile, this compound could be an ideal candidate for chemoprevention of breast and uterine cancers, while protecting against osteoporosis and cardiovascular disease." 07/01/2001 - "The combination of DHEA with a fourth generation SERM, such as EM-652 (SCH 57068), a compound having pure and potent antiestrogenic activity in the mammary gland and endometrium, could provide major benefits for women at menopause (inhibition of bone loss and serum cholesterol levels) with the associated major advantages of preventing breast and uterine cancer. "
5.	Endometrial Neoplasms (Endometrial Cancer) 12/01/2001 - "In order to minimize the risks of endometrial cancer and the development of resistance to antiestrogen therapy, we have synthesized the orally active antiestrogen EM-652 which is the most potent of the known antiestrogens and exerts pure antiestrogenic activity in the mammary gland and endometrium. " 08/15/1997 - "Thus, as assessed by their activity in the human Ishikawa endometrial carcinoma cells, EM-800 and EM-652 are the most potent known antiestrogens in Ishikawa cells, and, most importantly, they are devoid of the estrogenic activity observed in these human endometrial cancer cells with (Z)-4-OH-tamoxifen, (Z)-4-OH-toremifene, droloxifene, and raloxifene."

Related Drugs and Biologics

1.	Selective Estrogen Receptor Modulators (SERM)
2.	Estrogens (Estrogen)
3.	Dehydroepiandrosterone (DHEA)
4.	Estrogen Receptor Modulators (Antiestrogen)
5.	EM 800
6.	Tamoxifen
7.	droloxifene
8.	ritetronium
9.	Raloxifene Hydrochloride (Evista)
10.	Lipids

Related Therapies and Procedures

1.	Ovariectomy (Oophorectomy)
2.	Therapeutics
3.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
4.	Chemoprevention